Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF13C, VAY-736(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15621MR)

This product GTTS-WQ15621MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF13C gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_052945.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 115650
UniProt ID Q96RJ3
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF13C, VAY-736(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ15621MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ1525MR IVTScrip™ mRNA-Anti-MSTN, ACE-031(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ACE-031
GTTS-WQ2061MR IVTScrip™ mRNA-Anti-Canlupfam PDCD1, AH-PD1(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AH-PD1
GTTS-WQ13208MR IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PF-04950615
GTTS-WQ4647MR IVTScrip™ mRNA-Anti-FGFR1, BMS-986036(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BMS-986036
GTTS-WQ6815MR IVTScrip™ mRNA-Anti-STEAP1, DSTP-3086S(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA DSTP-3086S
GTTS-WQ3111MR IVTScrip™ mRNA-Anti-B4GALNT1, APN311(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA APN311
GTTS-WQ11263MR IVTScrip™ mRNA-Anti-CD274, MEDI4736(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MEDI4736
GTTS-WQ9407MR IVTScrip™ mRNA-Anti-PTPRC, Iomab-B(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA Iomab-B
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW